Complement Inhibitor Compounds Modulating Cascade for Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for modulating the complement system to treat complement-associated diseases often increase susceptibility to infections and are only approved for orphan indications, leaving a need for effective treatments for more prevalent disease states.
Innovation Solution
The use of compounds of Formula I, such as 5,7-dimethoxy-2-{4-[4-(propan-2-yl)piperazin-1-yl]phenyl}-3,4-dihydroquinazolin-4-one, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or hydrates, to modulate the complement cascade and treat diseases like paroxysmal nocturnal hemoglobinuria, familial CD59 deficiency, and other complement-associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for modulating the complement system are used to treat complement-associated diseases, then the complement cascade is modulated, but susceptibility to infections increases
Solution Approach 1:
The patent modifies the chemical structure of complement inhibitor compounds by changing parameters such as substituting different R groups (R1-R7) and W positions in the core molecular framework. This allows optimization of the compounds' binding affinity to complement factors while reducing off-target effects that cause infection susceptibility, thus treating complement-associated diseases with improved safety profiles
2Reliability
If current therapies for modulating the complement system are used, then complement-associated diseases are treated, but the therapies are only approved for orphan indications
Solution Approach 1:
The patent develops complement-modulating compounds with broad-spectrum activity that can treat multiple types of complement-associated diseases including but not limited to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and other prevalent inflammatory and autoimmune conditions. This multi-functional approach expands the therapeutic utility beyond orphan indications to commonly occurring diseases
3Reliability
If compounds of Formula I are used to modulate the complement cascade, then the expression and secretion of complement components are reduced, but the mechanism of action requires precise molecular interaction
Solution Approach 1:
The patent employs small molecule compounds as intermediaries that bridge the gap between therapeutic administration and complement system modulation. These compounds act as mediators by binding to specific complement factors (such as C3, C5, or regulatory proteins) and inducing conformational changes that reduce complement component expression and secretion, thereby simplifying the overall therapeutic mechanism while maintaining reliable complement system modulation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.